Abstract Number: 0584 • ACR Convergence 2025
Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
Background/Purpose: The concept of difficult-to-Manage axial spondyloarthritis (axSpA D2M), recently introduced by ASAS, describes patients who fail ≥2 lines of b-tsDMARDs treatment and remain active…Abstract Number: 2409 • ACR Convergence 2025
Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study
Background/Purpose: The Cutaneous Lupus Activity Investigator’s Global Assessment-Revised (CLA-IGA-R) is an emerging clinician-reported outcome measure for severity of Cutaneous Lupus Erythematosus (CLE) disease activity, developed…Abstract Number: 2253 • ACR Convergence 2025
Wrist-worn Wearable Device Data Can Be a New Digital Biomarker For Disease Activity In Rheumatoid Arthritis: a Multicenter Single-arm Prospective Study
Background/Purpose: Previous studies have estimated physical and mental states using wearable device data such as from smartwatches [1–3]. This study aimed to identify digital biomarkers…Abstract Number: 1675 • ACR Convergence 2025
Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)
Background/Purpose: A substantial number of patients with rheumatoid arthritis (RA) experience treatment failure, incomplete response, or intolerance to TNFis (TNFi-IR). Neuroimmune modulation using an implantable…Abstract Number: 1433 • ACR Convergence 2025
Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort
Background/Purpose: The concept of Difficult-to-Manage Axial Spondyloarthritis (D2M-ax-SpA) was recently introduced by the Assessment of Spondyloarthritis International Society (ASAS). According to this new definition, D2M-ax-SpA…Abstract Number: 1312 • ACR Convergence 2025
Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department
Background/Purpose: The objective of this study was to identify clusters of patients with rheumatoid arthritis (RA) in clinical practice, according to evolution of disease activity…Abstract Number: 0648 • ACR Convergence 2025
Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiorgan organ damage, and early mortality. Anifrolumab (ANI), a human monoclonal antibody targeting the…Abstract Number: 0495 • ACR Convergence 2025
Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
Background/Purpose: Iguratimod (IGU), an oral synthetic disease-modifying antirheumatic drug (DMARD), has shown significant efficacy and safety in rheumatoid arthritis (RA) when combined with methotrexate (MTX)…Abstract Number: 0409 • ACR Convergence 2025
Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Outcome assessment is essential to optimize care for patients with juvenile idiopathic arthritis (JIA). Although disease activity and patient-reported outcomes (PROs) are different measures,…Abstract Number: 1509 • ACR Convergence 2025
Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Background/Purpose: Past reports have shown that serositis is a risk factor for organ damage in patients with SLE. However, the distinct clinical features of newly…Abstract Number: 2703 • ACR Convergence 2025
Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Background/Purpose: There is a need for better tools to monitor disease activity in giant cell arteritis (GCA). Prior studies demonstrated that vascular enhancement on cranial…Abstract Number: 2404 • ACR Convergence 2025
Clinical features of Elderly-onset Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic chronic disease characterized by a wide range of clinical and serological manifestations. It most commonly affects young…Abstract Number: 2246 • ACR Convergence 2025
Different Populations, Different SDAI Cut-Off? A Proposal for a New Remission Threshold in Brazilian RA Patients from a National Multicenter Study
Background/Purpose: Remission criteria in Rheumatoid Arthritis (RA) have continuously evolved to balance the risks of both overtreatment and undertreatment. The most recent update includes the…Abstract Number: 1661 • ACR Convergence 2025
Artificial Intelligence applied to Patient Reported Outcomes and Passive Physiologic Sensor Data can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
Background/Purpose: Remote therapeutic monitoring (RTM) and remote physiologic monitoring (RPM) programs have the potential to capture data between clinical visits and provide information back to…Abstract Number: 1430 • ACR Convergence 2025
Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis
Background/Purpose: In patients with axial spondyloarthritis (axSpA), high disease activity is a key indication for biological disease-modifying antirheumatic drug (bDMARD) initiation. The Axial Spondyloarthritis Disease…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 112
- Next Page »